| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.049 | 0.5 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |